Abstract
INTRODUCTION
The aim of this report is to provide a range of information-from detailed
market analyses through industry trends-to quantify and qualify the market for
therapeutic enzyme inhibitors with large markets and/or broad therapeutic
applications.
This report offers a broad detailed overview of enzyme inhibitors currently on
the market and those in late-stage clinical trials. The information and
analysis presented in this report are important assets in decision-making for
managers involved in business development, marketing, market research, product
development, mergers and acquisitions, licensing, business management,
investment banking and deal creation, and to consultants to the pharmaceutical
and biotechnology industry. The study provides a comprehensive analysis of the
current markets for enzyme inhibiting drugs and, in particular, the market
potential of promising drugs and technologies under development.
SCOPE OF STUDY
This report contains:
- The major current and emerging therapeutic markets for enzyme inhibitors
used in human therapeutics,
- A discussion of the biochemistry for enzyme inhibitors and classes of
enzyme inhibiting products with broad current or potential therapeutic
applications or large markets,
- A synopsis of more than 100 enzyme inhibitors, including those currently
marketed and those in Phase II or later development,
- An overview of the leading indications for available and emerging enzyme
inhibitors. These include selected indications for asthma and chronic
obstructive pulmonary disease (COPD), cardiovascular diseases, erectile
dysfunction, gastrointestinal disorders, hepatitis B virus infection,
hepatitis C virus infection, herpesvirus infections, human immunodeficiency
virus (HIV)/acquired immune deficiency syndrome (AIDS) and rheumatoid
arthritis and related inflammatory diseases,
- Forecasts for the global market, through 2011,
- Company Profiles emphasizing companies that lead the pharmaceutical and
biotechnology industry in the research and development of enzyme-inhibiting
drugs.
METHODOLOGY
The base year for this study is 2005. Figures are based on revenue figures at
the manufacturers' level and are projected at 2005 dollar value; that is,
inflation is not computed into the projection figures.
Information to prepare this study was derived from information obtained from
product managers, marketing strategists, research executives and others at
leading pharmaceutical and biotechnology companies that compete in the market
for enzyme inhibitors or which have products in development for this market.
INFORMATION SOURCES
The information and analyses presented in this report are based on an
extensive survey of the biotechnology and pharmaceutical industries as well as
a detailed examination of published literature and reports obtained from
regulatory authorities, medical research institutions, pharmaceutical trade
associations and national and world health organizations. Key information from
the business literature was used as to obtain expert opinion on commercial
potential and market sizes from industry professionals.
ABOUT THE AUTHOR
Lynn Gray has been a research analyst in biotechnology and life sciences since
1989 and with BCC since 1996. During that time, she has authored more than 20
research reports in the biomedical field for BCC Research.
View Cart
